Indeed, a retrospective analysis of 190 melanoma patients treated with anti-PD1 Abs in the USA showed that irAE occurrence was significantly associated with the efficacy (ORR, improved OS and PFS) of anti-PD1 Abs monotherapy, especially associated with cutaneous and arthritis-like irAEs [84]. This evidence concerns the gene PDCD1 and melanoma.